Randomized phase2 Study of IP vs. GP as the First-line Therapy Followed by Two Different Sequences as the 2nd or 3rd-line Therapy for Patients With Advanced NSCLC;
Cisplatin-based chemotherapy is currently considered to be the standard treatment in
advanced non-small cell lung cancer (NSCLC). However, overall response is only 30-40%,
suggesting that a majority of the patients do not respond to platinum. Subsequently, those
patients who experience treatment failure with platinum-based therapy typically received
pemetrexed or docetaxel as second-line treatment, with response rate of approximately 7% to
10%. The primary objective of this randomized phase II study is to compare the Response Rate
of each sequence of treatment approach in patients with advanced NSCLC. Additionally,
development of gene expression profiles and genotypes that can predict response to commonly
used chemotherapy may provide a unique opportunity to better utilize drugs shown to be
effective in first- or second-line therapy. Here, we will conduct a pharmacogenomic study to
provide rational approach to the treatment of NSCLC by developing predictors of cisplatin
(first-line agent) and pemetrexed or docetaxel (second-line agents) sensitivity and
demonstrating the clinical value of identifying the most appropriate drug on the basis of
sensitivity profile for the treatment regimen of each individual patient. Such an approach
is likely to maximize response to chemotherapy and may change the current empirical paradigm
of NSCLC therapy.
Interventional
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Response Rate
every 6 weeks
No
JI-YOUN HAN, M.D.
Principal Investigator
National Cancer Center
South Korea: Korea Food and Drug Administration (KFDA)
NCCCTS-08-371
NCT01003964
February 2009
July 2013
Name | Location |
---|